Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Dermatology
•
Hidradenitis Suppurativa
•
Primary Care
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
Pt has not responded to Humira or Cosentyx. Pt is declining to have any infusion options.
Related Questions
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
What is your approach to diagnosing and managing methotrexate-induced alopecia?
What is your typical steroid taper regimen for managing RA flares?
How do you approach management of a patient with multiple lung nodules and low titer +CCP but no active joint symptoms suggestive of RA?
How do you approach patients who identify so strongly with being sick or with a particular diagnostic label that it makes up a significant portion of their identity?
Would you have concerns with continuing denosumab for much longer than the available ten year clinical safety trial data for an individual with renal insufficiency with persistent osteoporosis/history of compression fractures?
How often do you recommend ophthalmologic screening exams for patients with sarcoidosis?
What are your vaccine recommendations while patients are on biologics?
What therapies have you found most effective for JAK-induced/associated acne (JAKcne)?